Opaleye Management Inc. Tricida, Inc. Transaction History

Opaleye Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 18, 2021	SELL	$4.52 - $7.8 $4.33 Million - $7.48 Million	-959,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.37 - $9.46 $4.19 Million - $9.07 Million	959,000 New	959,000 $6.76 Million
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $2.04 Million - $6.42 Million	-238,300 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $939,603 - $1.4 Million	44,300 Added 22.84%	238,300 $6.55 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $29,600 - $43,710	-1,000 Reduced 0.51%	194,000 $7.3 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $934,800 - $1.18 Million	30,000 Added 18.18%	195,000 $7.7 Million
Q1 2019 May 15, 2019	BUY	$19.96 - $38.62 $838,320 - $1.62 Million	42,000 Added 34.15%	165,000 $6.37 Million
Q4 2018 Feb 14, 2019	BUY	$23.57 - $32.33 $1.7 Million - $2.33 Million	72,000 Added 141.18%	123,000 $2.9 Million
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $1.15 Million - $2.01 Million	51,000 New	51,000 $1.56 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.